This enzyme is known as phosphogluconate dehydrogenase (6PGD), and it is considered to play a role in this malignancy by protecting against decompensated oxidative stress, allowing for more surveillance and improving PCa growth (Gillis et al., 2021). The gene discussed is PGD; the disease is posterior cortical atrophy.